The San Diego firm took a step in that direction on Tuesday, when it unveiled what it says will be the world’s largest ...
Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is ...
Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.
Join us for a webinar on how advances in target-based drug discovery are reshaping therapeutic design. We’ll explore ...
PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- Cell Surface Bio (CSB) announces the launch VeRSa-Select™, a custom antibody service providing scientists with unparalleled access to the highest quality ...
Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...
News-Medical.Net on MSN
OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.
Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.
The collaboration is designed to leverage DART as a solution to analyze New Frontier Labs’s data on its new class of anti-inflammatory drugs that exert their effects by reversibly altering the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback